Hedge Funds Are Buying Uroplasty, Inc. (UPI)

Page 1 of 2

Is Uroplasty, Inc. (NASDAQ:UPI) an excellent investment now? The smart money is taking an optimistic view. The number of bullish hedge fund bets went up by 1 in recent months.

At the moment, there are dozens of metrics market participants can use to monitor the equity markets. A couple of the most innovative are hedge fund and insider trading interest. At Insider Monkey, our studies have shown that, historically, those who follow the best picks of the top money managers can trounce the market by a superb margin (see just how much).

Just as beneficial, bullish insider trading sentiment is another way to parse down the world of equities. Just as you’d expect, there are plenty of incentives for an executive to sell shares of his or her company, but just one, very clear reason why they would initiate a purchase. Plenty of academic studies have demonstrated the useful potential of this tactic if piggybackers know where to look (learn more here).

With all of this in mind, we’re going to take a look at the recent action surrounding Uroplasty, Inc. (NASDAQ:UPI).

How are hedge funds trading Uroplasty, Inc. (NASDAQ:UPI)?

At year’s end, a total of 8 of the hedge funds we track were long in this stock, a change of 14% from one quarter earlier. With the smart money’s sentiment swirling, there exists an “upper tier” of noteworthy hedge fund managers who were boosting their stakes meaningfully.

According to our comprehensive database, Manatuck Hill Partners, managed by Mark Broach, holds the most valuable position in Uroplasty, Inc. (NASDAQ:UPI). Manatuck Hill Partners has a $5.8 million position in the stock, comprising 0.8% of its 13F portfolio. Sitting at the No. 2 spot is Samuel Isaly of OrbiMed Advisors, with a $5.7 million position; the fund has 0.2% of its 13F portfolio invested in the stock. Remaining hedgies that are bullish include Jacob Gottlieb’s Visium Asset Management, Joseph Edelman’s Perceptive Advisors and Richard Driehaus’s Driehaus Capital.

Uroplasty, Inc. (NASDAQ:UPI)As one would reasonably expect, specific money managers were leading the bulls’ herd. DAFNA Capital Management, managed by Nathan Fischel, created the most valuable position in Uroplasty, Inc. (NASDAQ:UPI). DAFNA Capital Management had 0.2 million invested in the company at the end of the quarter. Jim Simons’s Renaissance Technologies also made a $0 million investment in the stock during the quarter.

What have insiders been doing with Uroplasty, Inc. (NASDAQ:UPI)?

Insider purchases made by high-level executives is best served when the company we’re looking at has seen transactions within the past half-year. Over the last 180-day time frame, Uroplasty, Inc. (NASDAQ:UPI) has experienced zero unique insiders buying, and zero insider sales (see the details of insider trades here).

Let’s also take a look at hedge fund and insider activity in other stocks similar to Uroplasty, Inc. (NASDAQ:UPI). These stocks are Span-America Medical Systems, Inc. (NASDAQ:SPAN), Digirad Corporation (NASDAQ:DRAD), EnteroMedics Inc (NASDAQ:ETRM), Vision-Sciences, Inc. (NASDAQ:VSCI), and Theragenics Corporation (NYSE:TGX). This group of stocks are in the medical appliances & equipment industry and their market caps are similar to UPI’s market cap.

Page 1 of 2